According to Gasparro et al., the median survival of patients was significantly higher in RCC patients (of whom 84.6% were diagnosed with ccRCC) with a negative (48 months) than with a positive PSMA PET/CT result (24 months) (p = 0.001, hazard ratio (HR) 3.6, 95% CI 1.36–9.79) [61]. The gene discussed is FOLH1; the disease is nonpapillary renal cell carcinoma.